NDA 017078 · Impax Labs INC
Dexedrine Spansule
Dextroamphetamine Sulfate · Oral
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
Aug 2, 1976
Approved uses
1
Original approval plus efficacy supplements
Registered trials
183
36 Phase 3, 11 recruiting
FAERS reports
3,824
2,051 serious, 99 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION DEXEDRINE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DEXEDRINE, can result in overdose and death [see Overdosage ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DEXEDRINE, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout DEXEDRINE treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Drug Abuse and Dependence ] .
What it is approved for
From the label in effect Sep 25, 2025.
INDICATIONS AND USAGE DEXEDRINE is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 2, 1976 Original approval · Type 5 - New Formulation or New Manufacturer Other Important Information from FDA
3 products under this application
- DEXEDRINE SPANSULE · DEXTROAMPHETAMINE SULFATE 15MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- DEXEDRINE SPANSULE · DEXTROAMPHETAMINE SULFATE 5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- DEXEDRINE SPANSULE · DEXTROAMPHETAMINE SULFATE 10MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dextroamphetamine" as an intervention, any sponsor and status, largest first.
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01435759 · 1,197 participants · Start May 31, 2011 · Primary completion Jan 17, 2014
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg and 3 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Chino, California · 82 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436162 · 1,105 participants · Start Oct 19, 2011 · Primary completion Dec 10, 2013
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Antidepressant + Placebo · For: Major Depressive Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Costa Mesa, California · 101 sites in all
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)Pivotal-lookingRecruiting
International Peace Maternity and Child Health HospitalAcademic, hospital or other
NCT06006091 · 858 participants (planned) · Start Aug 1, 2023 · Primary completion Aug 1, 2026
Drug: Letrozole · For: Letrozole; Infertility, Female
Sites: Shanghai, China
- Open Label Extension in Adults With Binge Eating Disorder (BED)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT01657019 · 604 participants · Start Aug 21, 2012 · Primary completion Oct 21, 2014
Drug: Lisdexamfetamine dimesylate · For: Binge Eating Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 89 sites in all
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552902 · 549 participants · Start Apr 3, 2012 · Primary completion May 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Tucson, Arizona; Little Rock, Arkansas · 95 sites in all
- Safety of SPD465 in Treating Adults With ADHD.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152035 · 505 participants · Start Mar 10, 2005 · Primary completion Nov 7, 2006
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective651
- fatigue294
- nausea258
- anxiety257
- headache231
- depression220
- insomnia193
- feeling abnormal189
- somnolence188
- weight decreased155
- pain154
- dizziness141
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 87 |
| 2005 | 98 |
| 2006 | 72 |
| 2007 | 148 |
| 2008 | 65 |
| 2009 | 66 |
| 2010 | 60 |
| 2011 | 40 |
| 2012 | 57 |
| 2013 | 55 |
| 2014 | 56 |
| 2015 | 258 |
| 2016 | 654 |
| 2017 | 262 |
| 2018 | 290 |
| 2019 | 236 |
| 2020 | 270 |
| 2021 | 147 |
| 2022 | 193 |
| 2023 | 217 |
| 2024 | 213 |
| 2025 | 173 |
| 2026 | 107 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Safety of Stimulants Across Patient Populations: A Meta-Analysis.
Oliva HNP, Prudente TP, Mayerson TF, et al. · JAMA Netw Open 2025 · Meta-Analysis, Research Support, N.I.H., Extramural
- Could setmelanotide be the game-changer for acquired hypothalamic obesity?
van Santen HM, Denzer C, Müller HL · Front Endocrinol (Lausanne) 2023 · Randomized Controlled Trial
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS, Bisaga A, Arcadepani FB, et al. · Psychopharmacology (Berl) 2020 · Meta-Analysis, Systematic Review
- Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial.
Trotti LM, Blake T, Hoque R, et al. · CNS Drugs 2024 · Randomized Controlled Trial, Comparative Study
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
Sponsor: Impax Labs INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.